Table 1.
Patients' characteristics.
| Characteristic | Standard Value (Range) | Patients (n=94) |
|
| ||
| Mean age (years) | NA | 36.90±8.17 |
| Male gender (n, %) | NA | 85 (90.4%) |
| Body mass index (BMI) (kg/m2) | NA | 24.20±2.68 |
| BMI ≥ 25 (n, %) | NA | 36 (37.9%) |
| Aspartate aminotransferase (IU/L) | 15-40 | 29 (15-128) |
| Alanine aminotransferase (IU/L) | 3-35 | 40.5 (9-173) |
| Total bilirubin (umol/L) | 4-23.9 | 12.7 (5.6-32.5) |
| Albumin (g/L) | 36-51 | 45.5 (36.2-51.6) |
| g-Glutamyltransferase (IU/L) | 10-60 | 32.5 (12-283) |
| Alkaline phosphatase (IU/L) | 45-125 | 72.5 (33-207) |
| Platelets count (103/mm3) | 100–350 | 200.43±54.87 |
| Prothrombin time activity (%) | 70–120 | 96.18±11.68 |
| Fasting glucose (mmol/L) | 3.9-6.1 | 4.90 (3.64-8.61) |
| Fasting glucose ≥5.6 mmol/L (n, %) | ≥5.6 | 23 (24.5%) |
| Total cholesterol (mmol/L) | 3.1-5.7 | 4.78±0.84 |
| Triglyceride (mmol/L) | 0.34-1.92 | 1.19 (0.39-4.89) |
| Triglyceride ≥ 1.7 mmol/L (n, %) | ≥1.7 | 22 (23.4%) |
| HDL-cholesterol (mmol/L) | 0.78-2.00 | 1.15±0.23 |
| Reduced HDL-cholesterol (mmol/L) (n, %) | <1.03 in men <1.29 in women |
29 (30.8%) |
| LDL-cholesterol (mmol/L) | 2.07-3.10 | 3.17±0.83 |
| Elevated LDL-cholesterol (n, %) | >3.10 | 52 (55.3%) |
| HBeAg positive (n, %) | >1 | 38 (40.4%) |
| HBV-DNA (log10 IU/mL) | <20 IU/mL | 4.83 (1.54-8.68) ∗ |
| Ultrasonography score | ||
| 4/5 | NA | 0/28 |
| 6/7 | NA | 29/18 |
| 8/≥9 | NA | 11/8 |
| Fibrosis score (METAVIR) | ||
| F0 (n, %) | NA | 19 (20.2%) |
| F1 (n, %) | NA | 28 (29.7%) |
| F2 (n, %) | NA | 16 (17.0%) |
| F3 (n, %) | NA | 17 (18.1%) |
| F4 (n, %) | NA | 14 (15.0%) |
| Hepatic steatosis | ||
| ≥5% | NA | 90 (95.7%) |
| 34-66% | NA | 3 (3.2%) |
| >66% | NA | 1 (1.1%) |
Unless otherwise indicated, data were expressed as means ± standard deviations or medians and ranges. ∗Eleven patients had undetectable HBV-DNA loads. HDL=high density lipoprotein; LDL= low-density lipoprotein; NA=not applicable.